Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
All categories, including reagents, instruments, contract services and genetic medicine, declined year on year. Results were affected by the downturn in the global life sciences research market, cuts in U.S. research grants, intensifying competition from competitors in China, a decline in development projects in Japan's cell and gene therapy fields, and intensifying competition in genomic analysis. The cost of sales increased due to changes in the sales mix, while selling, general and administrative expenses increased due to Curio's acquisition-related expenses and amortization of goodwill.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥40,318 million (YoY -10.5%) |
| Operating profit | ¥-4,688 million |
| Ordinary income | ¥-4,992 million |
| Profit attributable to owners of the parent | ¥-9,599 million |
| Net income per share | ¥(79.72) |
| Operating Margin | -11.6 % |
| Equity ratio | End of the current fiscal period 77.6 / End of previous period 92.2 |
| Total assets | ¥133,658 million |
| Net assets | ¥103,967 million |
| Cash flows from operating activities | ¥3,582 million |
| Cash flows from investing activities | ¥-18,680 million |
| Cash flows from financing activities | ¥6,121 million |
| Cash and cash equivalents at end of period | ¥18,214 million |
| Full-year earnings forecast | Net Sales ¥44,000 million (YoY +9.1%) / Operating profit ¥-2,700 million / Ordinary income ¥-3,000 million / Net income ¥-6,400 million |
| Annual Dividend Forecast | 0 yen and sen → Not disclosed |
| Payout ratio | 196.5 |
| Regional sales | Japan Current fiscal year ¥14,139 million / Previous period ¥15,062 million / United States Current fiscal year ¥12,255 million / Previous period ¥12,997 million / China Current fiscal year ¥5,378 million / Previous period ¥8,522 million / Asia excluding Japan and China Current fiscal year ¥2,763 million / Previous period ¥2,855 million / Europe Current fiscal year ¥5,409 million / Previous period ¥5,248 million / Other Current fiscal year ¥372 million / Previous period ¥353 million |
| Depreciation and amortization | ¥4,136 million |
| Impairment loss | ¥3,876 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥38 million / Reversal of asset retirement obligations ¥74 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥96 million / Impairment loss ¥3,876 million / Other ¥345 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name Curio Bioscience, Inc. / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | The tender offer by TAKARA HOLDINGS INC. was successful, and following the required procedures, the company's shares are scheduled to be delisted on 12 June 2026. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 120,415,600 Shares |
| Treasury Shares at Period-End | 300 Shares |
| Factors Behind Changes in Business Performance | All categories, including reagents, instruments, contract services and genetic medicine, declined year on year. Results were affected by the downturn in the global life sciences research market, cuts in U.S. research grants, intensifying competition from competitors in China, a decline in development projects in Japan's cell and gene therapy fields, and intensifying competition in genomic analysis. The cost of sales increased due to changes in the sales mix, while selling, general and administrative expenses increased due to Curio's acquisition-related expenses and amortization of goodwill. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decline in sales was attributable to the downturn in the global life sciences research market, cuts in U.S. research grants, intensifying competition in China, a decline in development projects in Japan's cell and gene therapy fields, and intensifying competition in genomic analysis. The company also recorded acquisition-related expenses and amortization of goodwill related to Curio Bioscience, Inc., as well as impairment losses on contract manufacturing facilities that were not in operation and other assets.